Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Alnylam Pharmaceuticals

Biotech & Life Sciences · Cambridge, United States · Founded 2002 · IPO 2004 Decacorn

Develops novel therapeutics-based RNAi and provides overviews of recent drug development programs

Valuation
$40B
Market cap · May/2026
Revenue
$2.99B
Latest reported FY
EBITDA
$676M
Latest reported FY
Featured in Decacorn$10B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

9 investors on Alnylam Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage
Merck & Co.
Abingworth
Series B+ 7 investors entered at this stage
Cardinal Partners
ARCH Venture Partners
Massachusetts Institute of Technology
Polaris Partners
Max Planck Society
Max Planck Innovation
Atlas Venture

Alnylam Pharmaceuticals mafia

Startups founded by Alnylam Pharmaceuticals alumni

Former Alnylam Pharmaceuticals employees who went on to start their own companies. Sorted by Dealroom signal score.

Scholar RockEst. 2012
Nagesh K. MahanthappaUnited States
Signal score93
Imbria PharmaceuticalsEst. 2018
David-Alexandre "Da" GrosUnited States
Signal score87
Arpeggio BioEst. 2017
Tim ReadUnited States
Signal score87
Vesigen TherapeuticsEst. 2019
Robert MillmanUnited States
Signal score62
OvaScienceEst. 2011
Christoph WestphalUnited States
Signal score61
Verseau TherapeuticsEst. 2017
Tatiana NovobrantsevaUnited States
Signal score59
Sirtris PharmaceuticalsEst. 2004
Paul SchimmelUnited States
Signal score59
AerskaEst. 2025
SMStuart MilsteinIreland
Signal score58
PixarBioEst. 2013
Robert LangerUnited States
Signal score58
Forge TherapeuticsEst. 2015
ZZZachary ZimmermanUnited States
Signal score57
Disarm TherapeuticsEst. 2016
JRJason RhodesUnited States
Signal score53
KinesisEst. 2013
Barry GreeneIreland
Signal score44

Book a demo to explore the full alumni network →

Global footprint

Where Alnylam Pharmaceuticals has talent and traffic

AI talent share
0.4% of workforce is AI talent
(12 of 2,822 staff)
Core AI30.11%
Other AI90.32%
Non-AI workforce2,81099.57%
Workforce by country
28 countries with
team presence
🇺🇸 United States79.2%
🇬🇧 United Kingdom5%
🇳🇱 Netherlands2.3%
🇨🇭 Switzerland2.3%
🇩🇪 Germany1.8%
Top 5 of 28 shown
Web traffic by country
80K monthly visits
across markets
🇺🇸 United States58.5%
🇬🇧 United Kingdom9%
🇨🇦 Canada4.4%
🇮🇳 India4.1%
🏳️ Korea3.6%
Top 5 markets shown

Patent intelligence

$573M patent portfolio · 448 active families

Estimated portfolio value
$573M
1.4% of market cap · 3.5× smaller than top peer Ablynx ($2B)
448 active patent families
Where Alnylam Pharmaceuticals innovates Molecular biologyDiseaseDouble strandCell biologyGene expression

Where Alnylam Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Alnylam Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Alnylam Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Alnylam Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alnylam Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles